Stock Picks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like we are about to fly. Seller is just about out of shares.
Big buying gonna come in with any type of news next week!
Nope. Convertibles from the old management just hit this week. Not looking good until they are gone.
It’s a new company. New management and new revenue.
I have no clue what the old company did. You can bash the old company as much as you want.
You can’t bash the new company until they announce what’s in it.
I have no clue about the past company. I’m looking forward to them announcing what is going into the new company.
Everyone is buying. The naked short is just shorting a sh*t ton. Don’t be fooled
Very Large trust was split up
His mom owned the St. Louis rams and father was big in Hollywood. He’s very connected.
New billionaire CEO and no converts left tells us it is different this time.
Sweet! Financials out and now I’m hopeful we see news about what is being put into the company within the next week or 2. Holding my shares tight!
I’m expecting financials this week.
Then hopefully news in the next week or two about what assets are being put into the company. Load up!
Wow. Rafa is becoming a mega-company in front of our eyes. Just wait until you see Quarter 3.
$RAFA 2nd Quarter Results
*HIGHLIGHTS*
> $34,101,000 Sales Revenue
> $12,700,000 Gross Profit
> $5,090,000 Net Income
> $0.058 Net Income / per share
> $11,275,000 Cash on Hand
> Shares Outstanding 87,766,999
https://sec.report/otc/financial-report/297500
This guy is 0 for 10 on his last 10 post. Officially blocked. Keep on shorting and see what happens over the next few weeks.
Everyone is loading up now. .50 this year is not out of the question. Billionaire boys in charge now.
Blah blah. Post the same thing over and over again for the 3 people here.
This guy is Obsessed with me and writing the same thing over and over.
I’d like the GRYN motto to be “Earnings per share on deck”
Up 7.5%. Congrats to those who bought the dip.
You assume wrong. That is not free trading stock. It’s stock going to a entity that will own a percentage of the new company and it is locked up.
I have no clue about previous management or previous PRs. I came here when they announced the new CEO 3 weeks ago.
Again new management has very deep pockets and should be announcing what’s going into the company soon.
No. Just getting started. Once they announce the new company going into it, we explode. They’ve been working over a year on it.
No one is dumb enough to sell this when you’ve got big boy assets coming in and a billionaire coming in as CEO.
Great news! Lift off coming in 6-8 weeks baby!
Everyone will be mentioning it soon. Let the company come out and tell us what assets they are putting into it.
New management coming in. One of them is a billionaire. Big things happening. HOLD!
Should go around .08 this week. .15 cents by September. Rumor of big assets being put into it.
New management. Possibly some new assets coming in. HOLD!
No. Just this one.
My educated guess is it will be finished in September. It will show a company doing $90 million in revenue per year and earning $15+ million per year.
And with the 200 projects rolling out over the next few years, those numbers should go 10x relatively quickly.
No, it’s not. He moved onto some different penny stocks. We are happy to have him gone.
This is going .20 by end of year. Over $1 in 2022. Just be patient.
What’s shaking here? I’m anticipating some good news with the new management taking over.
Revenue and profits just keep on growing each quarter and I think they will double each year from here on out. Today was a great time to add if you are a long term investor.
For the 3rd time, that is not us. That is a different GTII in Canada.
They are both GTII. This board is for GTII in New York. (Global Tech Industries)
You posted news for GTII I’m Canada. (Green thumb)
There are 2 GTII tickers. This news is for the other one.
Great $RAFA Video! - Construction Project Video Update @ "Tashkent Pharma Park" cluster | July 30, 2021 in #Uzbekistan
Black small square Admin Building
Black small square Laboratory, Center of Pharmaceutical Products & Research Center & New Pharma University
Black small square Pharmaceutical Technical Center
Huge $RAFA News! Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build.
"Production of cancer drugs and drugs from human donor blood plasm." Total investment will amount to $85 million!!!
https://www.otcmarkets.com/stock/RAFA/news?id=314051
Wow. This is quite the project. This will equal major, major revenue for Rafa:
Great summary! We have a huge winner here. Thanks
New $Rafa Report...Price Target Raised to $16. Nice! Congrats, to everyone who is building a position here. The next few years look bright.
JULY 2021 RAFARMA IG EQUITY RESEARCH REPORT
Our Estimates
In this section we provide detail regarding our revenue, margin and cash flow estimates. Our estimates used in the multiple of revenues valuation approach are the same as those used for the DCF valuation. As we have discussed, there are a variety of factors that we expect will drive double digit topline growth over
the next several years. In 2021, we anticipate that the strong momentum from new partnerships and product launches will push revenues to over $119 million, in line with the company’s guidance. We anticipate conservatively that this proforma growth rate will continue in coming years as geographical penetration continues and sales efforts continue to gain momentum. 2021 to 2024 topline growth is conservatively forecasted to be 59% each year in our DCF model as the company reaches critical mass.
Rafarma is expected to use its consolidated businesses to achieve at least 2% penetration in the radio-pharmaceuticals, targeted drug delivery and AI therapies markets.
Although gross margins are anticipated to rise in 2021 and beyond due to the addition of higher margin products that make up a larger portion of total revenues, we have conservatively maintained the same gross margin as achieved in 2020. Over time, we expect that gross margins will converge to industry averages as
partnerships, manufacturing processes and sourcing are refined. Our analysis indicates industry gross margins of above 60%, however, we adopt a conservative approach and assume that Rafarma will only achieve a 59% margin in 2021 and beyond.
SG&A expenses are expected to grow at a slower rate than topline as many costs are fixed in nature and rise in step function as new capacity is added. The majority of SG&A is comprised of sales and marketing costs which are in lockstep with sales given the Company’s commission structure. The remaining SG&A is more or
less fixed and we expect Rafarma will continue to leverage this cost as revenues grow. Current SG&A of 11% is expected to fall in 2021 and beyond, however in our DCF model, we maintain this line item at 11%. Our estimates are used for both our DCF model and our multiple of forward EBITDA and revenues.
Ownership and Dilution
As of March 31, 2021, shares of common stock outstanding totaled 87.7 million, which includes all of the shares issued to Biocogency owners.
Earnings Summary
2H-2020 was a turning around period for Rafarma post reverse-merger with Biocogency. FY-2020 topline results were $74.730 million, a 59.42% increase over proforma results in the previous year. Net income from operations was $14.847 million pegging the earnings per share at 0.1692, and price to earnings ratio at
9.3381. While gross margin was 44.27%, operating margin was 25.53%. Cash balance was $5.4 million.
Valuation
RAFA currently trades at a forward EV to sales ratio of 5.38X using our FY-2021 revenue estimate of $119 million. Applying our revenue, growth and cash flow estimates, we calculate a price target by blending our EV/Sales and DCF valuations.
Target Price Summary
We believe double digit revenue growth over the next several years combined with sales synergies and continued relationship development with group purchasing organizations will result in substantial fixed cost leverage and profit growth. We apply a 5.94X multiple to our FY-2021 revenue estimate to generate a
revenue-based target price of $10.34.
Our DCF valuation applies a 12% discount rate to our five year cash flow forecast, which generates a present per-share value of $13.90. Refer to the following exhibit which summarizes our cash flow estimates and DCF calculations. Based on our valuation work, we have calculated a one year target price of $12.12, which is a 50/50 blend of our DCF and multiple of revenues target prices.
Summary
Rafarma Pharmaceuticals is levered to several key growth drivers, and demographic trends that are anticipated to maintain topline expansion in the double digit range for the foreseeable future. The combination of radio-pharmaceutical products, and targeted delivery products will benefit from sales force and product synergies that are anticipated to expand revenues at a substantially faster rate than expenses. The sales force has been growing consistently over the last year following a 2020 overhaul of the sales function. All the planned for growth segments have a history of developing, gaining approval and launching innovative products that address unmet needs in the anti-aging, immunotherapy, targeted delivery and nuclear medicine. Both company guidance and our estimates call for a double-digit proforma growth rate in 2021, and nearly $120 million in combined revenues. The company is also expected to be EBITDA positive on a full year basis in FY-2021 as well. Rafarma is trading at
a very favorable valuation relative to historical transactions in the space. Currently, the company is valued at 5.38X 2021 revenues.
The Nasdaq approval board has been working from home for well over a year now. It has definitely slowed up approval times.